Export of Celltrion/Samsung bioepis exceed ₩10trillion

Biosimilars

Celltrion's export amounted to 7.16 trillion won

Samsung Bioepis' exports amounted to 3.3649 trillion won

According to the Financial Supervisory Service on the 1st, four biosimilars, Celltrion Healthcare's Remsima, Truxima, Herzuma and Remsima SC, recorded a total of 1.5694 trillion won in exports last year.

 

It fell 2.0% from 1.616 trillion won in 2020, but exceeded 1 trillion won for the third consecutive year from 2019.

 

Celltrion Healthcare is an affiliate of Celltrion, and Celltrion Healthcare Holdings is the largest shareholder (24.3% stake).

 

Celltrion Healthcare receives antibody biosimilar products from Celltrion and sells them to global retailers.

 

Celltrion Healthcare sells four biosimilars, Remsima, Truxima, Herzuma and Remsima SC, in overseas markets.

 

Remsima's original drug is Janssen's Remicade.

 

Remsima SC is Remsima's injection formulation.

 

Truxima and Herzuma are biosimilars from Mabthera and Herceptin, respectively.

 

According to last year's export performance by item, Remsima recorded the largest export amount of 809.6 billion won.

 

It recorded the highest export performance ever, up 31.1% from 617.4 billion won in 2020.

 

Remsima SC exported 89.6 billion won last year, up 157.3% from the previous year.

 

Remsima and Remsima SC collaborated on a total of 899.2 billion won in exports last year.

 

Remsima is the first biosimilar product approved in 2012.

 

Remsima recorded the largest export of Celltrion's biosimilars every year, with Truxima leading the way with 786.8 billion won in 2019.

 

However, Remsima beat Truxima last year, re-establishing its lead in exports.

 

Truxima's exports amounted to 459.1 billion won last year, down 41.6% from the previous year.

 

The company explains that sales have decreased due to temporary supply schedule adjustments.

 

Celltrion Healthcare started selling Truxima in the U.S.

 

in 2020.

 

At this time, Truxima's supply decreased relatively last year as U.S.

 

sales partners supplied a large amount of Truxima's launch volume.

 

It is analyzed that growth has slowed down somewhat as competition for biosimilars intensified.

 

Truxima had a 25% prescription share of the U.S.

 

market in the fourth quarter of last year.

 

Truxima had a 34% share of the European market as of the third quarter of last year.

 

Herzuma's exports amounted to 211 billion won last year, up 29.8% from the previous year.

 

Herzuma took the lead in the Japanese market with a 51% share as of the third quarter of last year.

 

However, the European market has slowed down recently.

 

Herzuma had a 19% market share in Europe in the first quarter of 2020, but fell to 13% in the third quarter of last year.

 

Celltrion Healthcare, which was listed on the KOSDAQ market in 2017, has listed its export performance in its business report since 2014.

 

Remsima and Remsima SC recorded the largest export performance of 4.2742 trillion won since 2014.

 

Truxima, which has had export performance since 2017, posted 2.1783 trillion won in cumulative exports, while Herzuma's cumulative exports amounted to 693.9 billion won.

 

Celltrion Healthcare's export performance of four biosimilars recorded last year since 2014 totaled 7.16 trillion won.

 

Samsung Bioepis has also set a new sales record every year since 2016.

 

Samsung Bioepis posted 847 billion won in sales last year, up 9.0% from the previous year.

 

It is the largest since the company was established in 2012.

 

It has continued to grow recently, increasing 129.7% in three years from 368.7 billion won in 2018.

 

Annual Celltrion Healthcare biosimilar exports (unit: 1 million won, data: Financial Supervisory Service)

Most of Samsung Bioepis sales occur through overseas sales of its own biosimilar products.

 

Samsung Bioepis succeeded in commercializing biosimilar products of six biopharmaceuticals, including Enbrel, Remicade, Herceptin, HUMIRA, Avastin, and Lucentis.

 

In Europe, all six products have been licensed, and in the United States, five products have been approved for sale except Avastin.

 

Since Samsung Bioepis recorded sales of 765.9 billion won in 2019, its growth rate was only 1.5 % the following year.

 

In the early days of the COVID-19 crisis, the number of drug prescriptions decreased, resulting in a temporary market reduction.

 

Quarterly performance fluctuated as pre-orders from hospitals and wholesalers in Europe occurred with the aim of securing inventory in preparation for the prolonged COVID-19.

 

However, it recovered its growth last year due to the expansion of biosimilar sales in the U.S.

 

and Europe.

 

Samsung Bioepis' biosimilars are sold overseas by its partners Biogen and Organon.

 

Biogen will sell three types of biosimilars for autoimmune disease treatments: Enbrel, Remicade, and Humira in Europe.

 

Organon sells these three products in the rest of the world except Europe and South Korea.

 

In the United States, only Remicade biosimilars are sold.

 

Organon is also responsible for overseas sales of two types of biosimilars, Herceptin and Avastin.

 

The company's five biosimilars recorded a total of $1.255.1 billion (about 1.5 trillion won) in overseas markets last year.

 

It achieved its highest sales, up 11% from $1.125.8 billion in 2020.

 

Sales of biosimilars sold by Biogen reached 831.1 million dollars last year, up 4% from the previous year.

 

Organon sales rose 28% year-on-year to 424 million dollars.

 

Founded in 2012, Samsung Bioepis generated 43.7 billion won in sales for the first time in 2013.

 

In 2016, sales recorded 147.5 billion won as the overseas expansion of biosimilars began in earnest, and has continued to grow every year since then.

 

Samsung Bioepis has recorded cumulative sales of 3.3649 trillion won since its launch in 2012.

 

Most of Samsung Bioepis' sales come from overseas sales of biosimilars or profits from technology fees.

 

Domestic sales are insignificant.

 

According to IQVIA, a pharmaceutical research firm, Samsung Bioepis' sales of five biosimilars totaled only 13.2 billion won last year.

 

Celltrion and Samsung Bioepis biosimilars have collaborated on exports of a total of more than 10 trillion won.